OBJECTIVES: To investigate the prognostic value of some conventional bone markers and a number of other factors in terms of the survival of patients with hormone-resistant prostate cancer and bone metastases treated with chemotherapy. METHODS: The data of 141 patients were analyzed to verify the influence of the following factors on survival: bone-alkaline phosphatase, type I collagen propeptide, the carboxyterminal telopeptide of type I collagen, the urinary calcium/creatinine ratio, patient age, Karnofsky performance status, pathologic grade, duration of response to primary hormonal therapy, prostate-specific antigen, hemoglobin, lactate dehydrogenase, and extent of bone disease. RESULTS: When all the variables were simultaneously analyzed using the multivariate proportional hazard model, only Karnofsky performance status (P <0.005) and duration of response to primary hormonal therapy (P <0.0001) remained statistically significant. CONCLUSIONS: The results of this study suggest that bone-alkaline phosphatase, type I collagen propeptide, the carboxyterminal telopeptide of type I collagen, and the urinary calcium/creatinine ratio are not prognostic of survival in patients with hormone-resistant prostate cancer and bone metastases treated with chemotherapy.
OBJECTIVES: To investigate the prognostic value of some conventional bone markers and a number of other factors in terms of the survival of patients with hormone-resistant prostate cancer and bone metastases treated with chemotherapy. METHODS: The data of 141 patients were analyzed to verify the influence of the following factors on survival: bone-alkaline phosphatase, type I collagen propeptide, the carboxyterminal telopeptide of type I collagen, the urinary calcium/creatinine ratio, patient age, Karnofsky performance status, pathologic grade, duration of response to primary hormonal therapy, prostate-specific antigen, hemoglobin, lactate dehydrogenase, and extent of bone disease. RESULTS: When all the variables were simultaneously analyzed using the multivariate proportional hazard model, only Karnofsky performance status (P <0.005) and duration of response to primary hormonal therapy (P <0.0001) remained statistically significant. CONCLUSIONS: The results of this study suggest that bone-alkaline phosphatase, type I collagen propeptide, the carboxyterminal telopeptide of type I collagen, and the urinary calcium/creatinine ratio are not prognostic of survival in patients with hormone-resistant prostate cancer and bone metastases treated with chemotherapy.
Authors: Jeena Joseph; Yusuke Shiozawa; Younghun Jung; Jin Koo Kim; Elisabeth Pedersen; Anjali Mishra; Janet Linn Zalucha; Jingcheng Wang; Evan T Keller; Kenneth J Pienta; Russell S Taichman Journal: Mol Cancer Res Date: 2012-01-12 Impact factor: 5.852
Authors: Ilaria Pastina; Elisa Giovannetti; Aldo Chioni; Tristan M Sissung; Francesco Crea; Cinzia Orlandini; Douglas K Price; Claudia Cianci; William D Figg; Sergio Ricci; Romano Danesi Journal: BMC Cancer Date: 2010-09-27 Impact factor: 4.430
Authors: C Grávalos; C Rodríguez; A Sabino; M Á Seguí; J A Virizuela; A Carmona; J Cassinello; D Isla; C Jara; M Martín Journal: Clin Transl Oncol Date: 2016-11-28 Impact factor: 3.405
Authors: Leonard Chiu; Erin Wong; Carlo DeAngelis; Nicholas Chiu; Henry Lam; Rachel McDonald; Natalie Pulenzas; Julia Hamer; Nicholas Lao; Edward Chow Journal: J Bone Oncol Date: 2015-02-27 Impact factor: 4.072